Thromboprophylaxis for Hip Revision Arthroplasty: Can We Use the Recommendations for Primary Hip Surgery? A Cohort Study
The risk of thromboembolic events after hip revision arthroplasty might be higher than in primary hip arthroplasty. However, evidence regarding the use of thromboprophylaxis in revisions is scarce. The purpose of this study is to determine whether thromboprophylaxis recommendations for primary arthr...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2019
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23665
- Acceso en línea:
- https://doi.org/10.1177/1076029618820167
https://repository.urosario.edu.co/handle/10336/23665
- Palabra clave:
- Anticoagulant agent
Apixaban
Dabigatran
Enoxaparin
Fondaparinux
Rivaroxaban
Anticoagulant agent
Adult
Aged
Arthroplasty
Article
Body mass
Cohort analysis
Comparative study
Computed tomographic angiography
Controlled study
Deep vein thrombosis
Doppler flowmetry
Female
Hip arthroplasty
Hip replacement
Hip revision arthroplasty
Hip surgery
Hospitalization
Human
Lung embolism
Lung ventilation
Major clinical study
Male
Operation duration
Osteoarthritis
Prevalence
Priority journal
Retrospective study
Thrombosis prevention
Venous thromboembolism
Middle aged
Procedures
Very elderly
Adult
Aged
Aged, 80 and over
Anticoagulants
Cohort studies
Female
Humans
Male
Middle aged
Retrospective studies
Arthroplasty
Blood transfusion
Hip
Prevention and control
Reoperation
Replacement
Venous thromboembolism
replacement
hip
Arthroplasty
- Rights
- License
- Abierto (Texto Completo)